PartnershipMay 6, 2026, 07:52 AM
Galmed, Tissue Dynamics Partner on Cardiac Fibrosis Platform
AI Summary
Galmed Pharmaceuticals Ltd. announced a collaboration with Tissue Dynamics Ltd. to develop a novel human chronic cardiac fibrosis model. This platform is designed to accelerate the discovery and development of new Aramchol-based therapeutic approaches for complex fibrotic heart diseases, focusing on chronic post-MI remodeling and heart failure with preserved ejection fraction (HFpEF). The collaboration will leverage Tissue Dynamics' vascularized, sensor-embedded cardiac organoids and Galmed's expertise in SCD1 biology to investigate interventions that improve tissue repair and resolve fibrosis by correcting underlying metabolic dysfunction.
Key Highlights
- Galmed Pharmaceuticals and Tissue Dynamics to develop a human-centered chronic cardiac fibrosis platform.
- The platform aims to accelerate Aramchol-based therapeutic approaches for complex fibrotic heart diseases.
- Initial focus is on long-term effects of myocardial infarction (MI) and HFpEF.
- The model will link lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair.
- Utilizes Tissue Dynamics' vascularized, multichambered cardiac organoids with embedded metabolic sensors.
- Expected to support rapid evaluation of Aramchol-based candidates and dosing strategies.
- Aims to identify interventions that improve tissue repair and resolve fibrosis by correcting metabolic dysfunction.
Price Impact
More from GLMD